The indirect controlling shareholders of Huashen Technology (000790.SZ) increased their total shares by 1%
According to the Zhitong Finance App, Huashen Technology (000790.SZ) issued an announcement. As of the disclosure date of this announcement, the implementation period of this increase plan has passed. Chengdu Yuanhong Biotechnology Co., Ltd., the indirect controlling shareholder of the company, has increased its holdings of the company's shares by 6,280,000 shares through centralized bidding transactions through the Shenzhen Stock Exchange trading system, accounting for 1% of the current total share capital of the company, and the total amount paid is about 197636 million yuan. The current plan to increase its holdings has not yet been completed, and Chengdu Yuanhong will continue to increase its holdings in accordance with the holdings increase plan.
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
Yuandong Biotech (688513.SH): 0.9086% of shares have been repurchased
Gelonghui, May 6, 丨 Yuandong Biotech (688513.SH) announced that by the end of April 2024, the company had repurchased a total of 1,092 shares of the company through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09 (excluding transaction fees such as stamp duty and transaction fees).
Hengrui Pharmaceutical (600276.SH): cumulative repurchase of 0.22% of shares
Gelonghui, May 6, 丨 Hengrui Pharmaceutical (600276.SH) announced that as of April 30, 2024, the company had repurchased a total of 14,351,878 shares through centralized bidding transactions, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, the lowest price was 41.09 yuan/share, and the total amount paid was 634,665,849.66 yuan (excluding transaction fees).
Express News | Fosun Pharmaceuticals: The holding subsidiary was approved for clinical trials by the US FDA
Express News | Shanghai Pharmaceuticals: Levosimendan injection approved for production